




PHARMACEUTICAL 2020

Theriva Biologics Inc.
Rank 217 of 358





PHARMACEUTICAL 2020

Theriva Biologics Inc.
Rank 217 of 358

The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Theriva Biologics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 38%, being 1.7% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	16,426
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,275
Liabilities, Non-Current	473
Other Assets	442
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	283
Other Revenues	0
Property and Equipment	367
Research and Development	11,083
Selling, General and Administrative Expense	4,580

Output Variable	Value in 1000 USD
Assets	17,235
Liabilities	5,748
Expenses	15,663
Revenues	0
Stockholders Equity	11,487
Net Income	-15,380
Comprehensive Net Income	-15,380
Economic Capital Ratio	38%